Relation between baseline risk and treatment decisions in non-ST elevation acute coronary syndromes: An examination of international practice patterns

Heart

Volumn 91, Issue 7, 2005, Pages 876-881

  Kaul, Padma ^a,b   Newby, L K ^b   Fu, Y ^a   Mark, D B ^b   Goodman, S G ^c   Wagner, G S ^b   Harrington, R A ^b   Granger, C B ^b   Van De Werf, F ^d   Ohman, E M ^e   Armstrong, P W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DUKE UNIVERSITY   (United States)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; AUSTRALIA; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DECISION MAKING; ELECTROCARDIOGRAM; EUROPE; FEMALE; GEOGRAPHIC DISTRIBUTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MULTICENTER STUDY; NEW ZEALAND; NON ST ELEVATION CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; ST SEGMENT; ST SEGMENT DEPRESSION; SURVIVAL; UNITED STATES;

ACUTE DISEASE; AGED; AUSTRALASIA; CANADA; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; CORONARY DISEASE; DECISION MAKING; ELECTROCARDIOGRAPHY; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL REPERFUSION; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; SYNDROME; UNITED STATES;

EID: 21044441654     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.042887     Document Type: Article

References (23)

1. Wallentin L. Non-ST-elevation acute coronary syndrome: fuel for the Invasive strategy. Lancet 2002;360:738-9.
2. Kaul P, Newby KL, Fu Y, for the PARAGON-B Investigators, et al. Troponin T and quantitative ST-segment depression offer complementary prognostic information In the risk stratification of acute coronary syndrome patients. J Am Coll Cardiol 2003;41:371-80.
3. Kaul P, Fu Y, Chang W-C, for the PARAGON-A and GUSTO-IIB Investigators, et al. Prognostic value of ST-segment depression In acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIB. J Am Coll Cardiol 2001;38:64-71.
4. Holmvang L, Clemmensen P, Wagner G, et al. Admission standard electrocardiogram for early risk stratification In patients with unstable coronary artery disease not eligible for acute revascularization therapy: a thrombin inhibition in myocardial Infarction (TRIM) substudy. Am Heart J 1999;137:24-33.
5. Hyde TA, French JK, Wong CK, et al. Four year survival of patients with acute coronary syndromes without ST-segment elevation and prognostic significance of 0.5 mm ST-segment depression. Am J Cardiol 1999;84:379-85.
6. Holmvang L, Luscher MS, Clemmensen P, et al. Very early risk stratification using combined ECG and biochemical assessment in patients with unstable coronary artery disease: a thrombin inhibition in myocardial infarction (TRIM) substudy. Circulation 1998;98:2004-9.
7. FRISC II Investigators. Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective randomized multicenter study. FRISC II investigators. Lancet 1999;354:708-15.
8. Cannon CP, Weintraub WS, Demopoulos L, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87.
9. Solomon DH, Stone PH, Glynn RJ, et al. Use of risk stratification to identify patients with unstable angina least likeliest to benefit from an invasive versus conservative management strategy. J Am Coll Cardiol 2001;38:969-76.
10. GUSTO-IIB Investigators. The global use of strategies to open occluded coronary arteries: a comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. GUSTO-IIB investigators. N Engl J Med 1996;335:775-82.
11. PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa) inhibitor), heparin, or both in unstable angina. The PARAGON investigators. Circulation 1998;97:2386-95.
12. PARAGON-B Investigators. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. The PARAGON-B investigators. Circulation 2002;105:316-21.
13. Newby LK, Ohman EM, Christenson RH, et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: The PARAGON-B Troponin T substudy. Circulation 2001;103:2891-6.
14. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983;1:710-9.
15. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons, 1980:122-7.
16. Diderholm E, Andren B, Frostfeldt G, et al. ST depression in ECG at entry indicates severe coronary lesions and large benefits of an early invasive treatment strategy in unstable coronary artery disease: the FRISC II ECG substudy. Eur Heart J 2002;23:41-9.
17. Holmvang L, Clemmensen P, Lindahl B, et al. Quantitative analysis of the admission electrocardiogram identifies patients with unstable coronary artery disease who benefit the most from early invasive treatment. J Am Coll Cardiol 2003;41:905-15.
18. Califf RM, Peterson ED, Gibbons RJ, et al. Integrating quality into the cycle of therapeutic development. J Am Coll Cardiol 2002;40:1895-901.
19. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial inforction: a report of the American College of Cardiology/American Heart Association Task force on practice guidelines (committee on the management of patients with unstable angina). J Am Coll Cardiol 2000;36:970-1062.
20. Bertrand ME, Simoons ML, Fox KAA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task force of the European Society of Cardiology, Eur Heart J 2002;23:1809-40.
21. Akkerhuis KM, Deckers JW, Boersma E, et al. Geographic variability in outcomes within an international trail of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes: results from PURSUIT. Eur Heart J 2000;21:371-81.
22. Fox KAA, Goodman S, Bigonzi F, et al. Inter-regional differences and outcome in unstable angina: analysis of the international ESSENCE trial. Eur Heart J 2000;21:1433-9.
23. Yusuf S, Flather M, Pogue J, et al. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. Lancet 1998;352:507-14.